Skip to main content
VCbacked
Log inGet Started

Avalyn Pharma

Seattle, United States

Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.

$100.0M raised
Jul 2025
Series D
BiopharmaBiotechnologyMedicalPharmaceutical

Top Investors

Norwest Venture PartnersWellington ManagementCatalio Capital ManagementNovo HoldingsPerceptive Advisors

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Avalyn Pharma

How much funding has Avalyn Pharma raised?
Avalyn Pharma has raised $100.0M in total funding. The most recent round was Series D. The last funding was announced in July 2025.
Who are Avalyn Pharma's investors?
Avalyn Pharma's investors include Norwest Venture Partners, Wellington Management, Catalio Capital Management, Novo Holdings, Perceptive Advisors.
Where is Avalyn Pharma headquartered?
Avalyn Pharma is headquartered in Seattle, United States.
What does Avalyn Pharma do?
Avalyn Pharma is a biopharma company developing therapies for the treatment of idiopathic pulmonary fibrosis and other respiratory diseases.
What stage is Avalyn Pharma at?
Avalyn Pharma is at the Series D stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Avalyn Pharma — Funding & Investors." VCBacked, July 22, 2025, https://www.vcbacked.co/company/avalyn-pharma. Accessed June 4, 2026.
APA
VCBacked. (2025). Avalyn Pharma — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/avalyn-pharma
Wikipedia (cite web)
{{cite web |title=Avalyn Pharma — Funding & Investors |url=https://www.vcbacked.co/company/avalyn-pharma |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biopharma

View all
ParcelBio
San Francisco$13.2M
Modicus Prime
Austin
Latus Bio
Philadelphia
Ocugen
Malvern
Ember LifeSciences
Los Angeles$16.5M
ClearNote Health
San Diego